Literature DB >> 36090237

Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures.

Ka-Hoo Lam1, Caspar E P van Munster1, Marcus D'Souza2, Saskia Steinheimer3, Christian P Kamm3,4, Jessica Burggraaff1, Matthew Johnson5, Yordan Zaykov5, Jonas Dorn6, Frank Dahlke6, Ludwig Kappos2, Joep Killestein1, Bernard Uitdehaag1.   

Abstract

BACKGROUND: Assessing motor functioning is important to monitor the disease course of multiple sclerosis (MS). Video-assisted rating of classic neurologic tests and activities of daily living may improve the detection of changes in motor functioning. We investigated the value of using video-assisted composite measures for the detection of changes in mobility and upper extremity function (UEF).
METHODS: Forty-three patients with MS were recorded performing motor function tests before and during treatment with fampridine. Patients were classified as improved or not improved on mobility composite (MOB-COM) and UEF composite (UEF-COM) measures based on neurologists' ratings of the tests. The proportional agreements between the composite measures and the conventional measures-the Timed 25-Foot Walk test (T25FW) and the Nine-Hole Peg Test (NHPT)-were determined and compared with patient-perceived improvement, which was determined using patient-reported ratings of changes in mobility and UEF.
RESULTS: Agreement between MOB-COM and T25FW was 79.5%, and agreement between UEF-COM and NHPT was 82.1%. Twenty-six of 39 patients (66.7%) reported mobility improvement; 6 of these reports were confirmed by both T25FW and MOB-COM, 4 were confirmed by T25FW only, and 2 were confirmed by MOB-COM only. For UEF, 13 of 39 patients (33.3%) reported improvement; 3 of these were confirmed by the NHPT and 3 were confirmed by the UEF-COM.
CONCLUSIONS: Compared with the conventional NHPT measure, the video-assisted composite measure of UEF detected additional patient-perceived improvement. This was less evident for mobility measures. Video-assisted composite measures may enhance the detection of treatment effects in MS clinical practice and trials.
© 2022 Consortium of Multiple Sclerosis Centers.

Entities:  

Keywords:  clinical assessment; multiple sclerosis; rehabilitation; upper extremity function; video-assisted

Year:  2022        PMID: 36090237      PMCID: PMC9461716          DOI: 10.7224/1537-2073.2021-044

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  26 in total

1.  Measurement of health status. Ascertaining the minimal clinically important difference.

Authors:  R Jaeschke; J Singer; G H Guyatt
Journal:  Control Clin Trials       Date:  1989-12

2.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Authors:  G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby
Journal:  Brain       Date:  1999-05       Impact factor: 13.501

3.  Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.

Authors:  Ziv Savin; Izabella Lejbkowicz; Lea Glass-Marmor; Idit Lavi; Sara Rosenblum; Ariel Miller
Journal:  J Neurol Sci       Date:  2015-12-02       Impact factor: 3.181

Review 4.  Progressive multiple sclerosis: from pathophysiology to therapeutic strategies.

Authors:  Simon Faissner; Jason R Plemel; Ralf Gold; V Wee Yong
Journal:  Nat Rev Drug Discov       Date:  2019-08-09       Impact factor: 84.694

5.  Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Authors:  Raju Kapoor; Pei-Ran Ho; Nolan Campbell; Ih Chang; Aaron Deykin; Fiona Forrestal; Nisha Lucas; Bei Yu; Douglas L Arnold; Mark S Freedman; Myla D Goldman; Hans-Peter Hartung; Eva Kubala Havrdová; Douglas Jeffery; Aaron Miller; Finn Sellebjerg; Diego Cadavid; Dan Mikol; Deborah Steiner
Journal:  Lancet Neurol       Date:  2018-03-12       Impact factor: 44.182

6.  Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.

Authors:  Keith C Hayes
Journal:  Neuropsychiatr Dis Treat       Date:  2011-04-28       Impact factor: 2.570

7.  The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.

Authors:  Peter Feys; Ilse Lamers; Gordon Francis; Ralph Benedict; Glenn Phillips; Nicholas LaRocca; Lynn D Hudson; Richard Rudick
Journal:  Mult Scler       Date:  2017-02-16       Impact factor: 6.312

8.  Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.

Authors:  Robert W Motl; Jeffrey A Cohen; Ralph Benedict; Glenn Phillips; Nicholas LaRocca; Lynn D Hudson; Richard Rudick
Journal:  Mult Scler       Date:  2017-02-16       Impact factor: 6.312

9.  Usability and Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using Depth-Sensing Computer Vision.

Authors:  Cecily Morrison; Marcus D'Souza; Kit Huckvale; Jonas F Dorn; Jessica Burggraaff; Christian Philipp Kamm; Saskia Marie Steinheimer; Peter Kontschieder; Antonio Criminisi; Bernard Uitdehaag; Frank Dahlke; Ludwig Kappos; Abigail Sellen
Journal:  JMIR Hum Factors       Date:  2015-06-24

10.  Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.

Authors:  Caspar Ep van Munster; Marcus D'Souza; Saskia Steinheimer; Christian P Kamm; Jessica Burggraaff; Manuela Diederich; Kristina Kravalis; Jonas Dorn; Lorcan Walsh; Frank Dahlke; Ludwig Kappos; Bernard Mj Uitdehaag
Journal:  Mult Scler       Date:  2018-08-31       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.